BioLargo Reports Record Results
WESTMINSTER, CA / ACCESSWIRE / November 15, 2018 / BioLargo, Inc. (OTCQB: BLGO), developer of sustainable science and technologies and a full-service environmental engineering company, today announced the filing of its 10-Q quarterly report:
- Sales increased 147% for the nine months ended September 30, 2018, compared with the nine months ended September 30, 2017
- Monthly revenues exceeded expenses in the engineering division (BLEST) for the first time (in October)
- Two pre-commercial field pilot projects are underway for the company’s AOS clean water technology and two more are in final stages of preparation. These pilots represent a landmark in AOS development, as they will pave the way for future commercial trials and market launch
- Clyra Medical Technologies management met with the FDA in Washington DC to determine a clear pathway for clearance on its product submission under Section 510(k)
- Details on a series of completed bridge financing arrangements
- A Form S-1 that was filed with the SEC to pursue a public offering to raise capital to meet Nasdaq listing requirements that will be led by H.C. Wainwright & Co., LLC
The 10-Q quarterly report can be accessed here: LINK.
BioLargo President and CEO Dennis Calvert commented, “The future is bright for BioLargo. Our disruptive odor and VOC control product CupriDyne Clean represents our first significant commercial success that is unfolding, and we believe our two other innovative technology platforms – Clyra and the AOS – will follow in similar fashion soon. Our success with CupriDyne Clean is an example of our business model succeeding. We leverage innovative high-tech products that are meaningful in purpose and serve as cornerstones of a commercial strategy. We combine them with services, value, talent and partnerships to create a disruptive platform that wins market share. Our engineering group, BLEST has been instrumental in our efforts to scale-up and prepare for commercial readiness for our AOS clean water technology while at the same time it has been building its outside services clients that now include regional utilities, healthcare and Fortune 500 companies. We are thankful for the continued support of our stockholders and believe 2019 will be a great year.”
About BioLargo, Inc.
BioLargo, Inc. is an innovative technology developer and environmental engineering company driven by a mission to “make life better” by delivering robust, sustainable solutions for a broad range of industries and applications, with a focus on clean water, clean air, and advanced wound care. We develop and commercialize disruptive technologies by providing the capital, support, and expertise to expedite them from “cradle” to “maturity” (www.biolargo.com). Our engineering division features experienced professional engineers dedicated to integrity, reliability, and environmental stewardship (www.biolargoengineering.com). Our industrial odor control division, Odor-No-More (www.odornomore.com) features CupriDyne Clean Industrial Odor Eliminator (www.cupridyne.com), which eliminates the odor-causing compounds and VOCs rather than masking them, and is now winning over leading companies in the solid waste handling and wastewater industries and other industries that contend with malodors and VOCs. Our subsidiary BioLargo Water (www.biolargowater.ca) develops the Advanced Oxidation System “AOS,” a disruptive industrial water treatment technology designed to eliminate waterborne pathogens and recalcitrant contaminants with better energy-efficiency and lower operational costs than incumbent technologies. Our subsidiary Clyra Medical (www.clyramedical.com) features effective and gentle solutions for chronic infected wounds to promote infection control and regenerative tissue therapy.
Dennis Calvert President and CEO BioLargo, Inc. 949-643-9540 x2
Safe Harbor Act
This press release includes “forward-looking statements” within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Actual results may differ from expectations, estimates and projections and, consequently, you should not rely on these forward-looking statements as predictions of future events. Words such as “expect,” “estimate,” “project,” “budget,” “forecast,” “anticipate,” “intend,” “plan,” “may,” “will,” “could,” “should,” “believes,” “predicts,” “potential,” “continue,” and similar expressions are intended to identify such forward-looking statements. These forward-looking statements involve significant risks and uncertainties that could cause the actual results to differ materially from the expected results.
SOURCE: BioLargo, Inc.